IGI Labs (IG) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
IGI Laboratories Announces Second Quarter 2015 Results
July 23, 2015 4:05 PM EDTBUENA, N.J., July 23, 2015 /PRNewswire/ --Â IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company, announced its financial results for the second quarter ended June 30, 2015.
Second Quarter 2015 Highlights
Total revenues of $8.9 million in the second quarter of 2015, an increase of 37% over the same quarter in 2014 Total net revenues generated from the sale of IGI label generic topical pharmaceutical products for the three months ended June 30, 2015 and 2014 of $6.7 million and $3.4... MoreIGI Laboratories, Inc. Announces Sixth ANDA Submission Of 2015
July 23, 2015 4:02 PM EDTBUENA, N.J., July 23, 2015 /PRNewswire/ --Â IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has submitted its sixth abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-eight.
Jason Grenfell-Gardner, President and CEO of the Company, commented, "We believe our current pipeline of twenty-eight submissions, exclusive of... More
